XML 29 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and contingencies - Neurocrine Collaboration Agreement - (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jun. 30, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
item
$ / shares
shares
Mar. 31, 2020
USD ($)
item
Mar. 31, 2019
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
Allocation of Transaction Price          
Related party collaboration receivable     $ 16,283   $ 18,496
Neurocrine Collaboration Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option   50.00%      
Allocation of Transaction Price          
Related party collaboration receivable     $ 16,300    
Neurocrine Collaboration Agreement | Parkinson's Program          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option after paying rate-shifting fee   0.45%      
Neurocrine Collaboration Agreement | FA Program          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option   0.40%      
Neurocrine Collaboration Agreement | Neurocrine          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of collaboration programs | item   4      
Number of discovery programs | item   2 2    
Number of targets | item   8      
Upfront payment $ 115,000 $ 115,000      
Purchase of common stock, shares | shares 4,179,728 4,179,728      
Purchase of common stock $ 5,000 $ 50,000      
Price per share | $ / shares   $ 11.9625   $ 11.9625  
Estimated cost reimbursement 431,100   $ 367,700    
Termination period   10 years      
Period of advance notice for termination prior to first commercial sale     180 days    
Period of advance notice for termination after first commercial sale     1 year    
Discount related to equity investment 27,600        
Equity investment 50,000        
Allocation of Transaction Price          
Allocation of variable consideration     $ 367,741    
Allocation of fixed consideration 92,400   92,382    
Revenue recognized     14,500 $ 1,900  
Deferred revenue     65,400    
Related party collaboration receivable     9,800    
Costs to obtain collaboration agreement     800    
Consideration received $ 5,000        
Neurocrine Collaboration Agreement | Neurocrine | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of reduction in royalty payments   50.00%      
Neurocrine Collaboration Agreement | Neurocrine | VY-AADC          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option   0.60%      
Percentage of profit or loss under co-co option after paying rate-shifting fee   0.55%      
Allocation of Transaction Price          
Allocation of variable consideration     110,187    
Allocation of fixed consideration     80,373    
Neurocrine Collaboration Agreement | Neurocrine | Parkinson's Program          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option   50.00%      
Rate-shifting fee   $ 35,000      
Neurocrine Collaboration Agreement | Neurocrine | FA Program          
Allocation of Transaction Price          
Allocation of variable consideration     113,392    
Allocation of fixed consideration     6,005    
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 1          
Allocation of Transaction Price          
Allocation of variable consideration     72,647    
Allocation of fixed consideration     3,002    
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 2          
Allocation of Transaction Price          
Allocation of variable consideration     71,515    
Allocation of fixed consideration     $ 3,002    
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | VY-AADC          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate maximum milestone payments to be received from collaborative partner   170,000      
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | FA Program          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate maximum milestone payments to be received from collaborative partner   195,000      
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | Discovery program 1          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate maximum milestone payments to be received from collaborative partner   130,000      
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | Discovery program 2          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate milestone payments   130,000      
Neurocrine Collaboration Agreement | Neurocrine | Commercial Milestone          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Per Milestone, maximum milestone payments to be received from collaborative partner   275,000      
Aggregate maximum milestone payments to be received from collaborative partner   $ 1,100,000